2022年12月最新中科院JCR期刊分区表数据（升级版）已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | CANCER RESEARCH CANCER RES LetPub评分 9.3
54人评分
我要评分
声誉 10.0 影响力 8.8 速度 9.2 | |||||||||||||||||||||
| 期刊ISSN | 0008-5472 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| E-ISSN | 1538-7445 | |||||||||||||||||||||
| 2021-2022最新影响因子 （数据来源于搜索引擎） | 注册或登录后，查看影响因子和历年趋势图 | |||||||||||||||||||||
| 2021-2022自引率 | 1.00%注册或登录后，查看自引率趋势图 | |||||||||||||||||||||
| h-index | 411 | |||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||
| 期刊简介 | Cancer Research is the most frequently cited cancer journal in the world. The journal publishes original studies, reviews, and opinion pieces offering significance and broad impact to a diverse audience spanning basic, preclinical, clinical, prevention and epidemiological research. Cancer Research seeks manuscripts that offer pathobiological and translational impact to inform the personal, clinical, and societal problems posed by cancer. The main scope of the Journal is captured in its primary subsections, which focus on molecular and cellular pathobiology, tumor and stem cell biology, therapeutics and targets, microenvironment and immunology, prevention and epidemiology, and integrated systems and technology. | |||||||||||||||||||||
| 期刊官方网站 | http://cancerres.aacrjournals.org/ | |||||||||||||||||||||
| 期刊投稿网址 | http://can.msubmit.net/cgi-bin/main.plex | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404 | |||||||||||||||||||||
| 出版商 | American Association for Cancer Research Inc. | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Semimonthly | |||||||||||||||||||||
| 出版年份 | 1941 | |||||||||||||||||||||
| 年文章数 | 492注册或登录后，查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 2.51% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 92.48% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2021-2022年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 注册或登录后，查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0008-5472%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均2.5月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 约30% | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 注册或登录后，查看自引率趋势图 |
| 注册或登录后，查看中科院SCI期刊分区趋势图 |
| 注册或登录后，查看年文章数趋势图 |
| 中国学者近期发表的论文 | |
| 1. | AKT as a Therapeutic Target for Cancer. Author: Song M#1,2, Bode AM#3, Dong Z4,2,3,5, Lee MH4,2,5. Journal: Cancer Res. 2019 Mar 15;79(6):1019-1031. doi: 10.1158/0008-5472.CAN-18-2738. Epub 2019 Feb 26. PubMed DOI |
| 2. | Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer. Author: Cao D#1,2,3, Qi Z#4, Pang Y#5, Li H#2,3,6, Xie H7, Wu J1,3, Huang Y1,3, Zhu Y1,3, Shen Y1,3, Zhu Y1,3, Dai B1,3, Hu X2, Ye D8,2,3, Wang Z9,1. Journal: Cancer Res. 2019 May 15;79(10):2604-2618. doi: 10.1158/0008-5472.CAN-18-3842. Epub 2019 Feb 26. PubMed DOI |
| 3. | Stabilized Peptide HDAC Inhibitors Derived from HDAC1 Substrate H3K56 for the Treatment of Cancer Stem-Like Cells In Vivo. Author: Wang D1, Li W1, Zhao R1, Chen L1, Liu N1, Tian Y2, Zhao H3, Xie M1, Lu F1, Fang Q1, Liang W4, Yin F5, Li Z5. Journal: Cancer Res. 2019 Apr 15;79(8):1769-1783. doi: 10.1158/0008-5472.CAN-18-1421. Epub 2019 Mar 6. PubMed DOI |
| 4. | Genome-Wide RNAi Screen Identifies PMPCB as a Therapeutic Vulnerability in EpCAM+ Hepatocellular Carcinoma. Author: Takai A#1, Dang H#1,2, Oishi N#1, Khatib S1, Martin SP1, Dominguez DA1, Luo J3, Bagni R4, Wu X4, Powell K4, Ye QH5, Jia HL5, Qin LX5, Chen J6, Mitchell GA6, Luo X6, Thorgeirsson SS1, Wang XW7. Journal: Cancer Res. 2019 May 1;79(9):2379-2391. doi: 10.1158/0008-5472.CAN-18-3015. Epub 2019 Mar 12. PubMed DOI |
| 5. | EBF1-Mediated Upregulation of Ribosome Assembly Factor PNO1 Contributes to Cancer Progression by Negatively Regulating the p53 Signaling Pathway. Author: Shen A#1,2, Chen Y#1,2,3, Liu L1,2,3, Huang Y1,2, Chen H1,2, Qi F1,2, Lin J1,2, Shen Z1,2, Wu X1,2, Wu M1,2, Li Q1,2, Qiu L1,2, Yu N1,2, Sferra TJ3, Peng J4,2. Journal: Cancer Res. 2019 May 1;79(9):2257-2270. doi: 10.1158/0008-5472.CAN-18-3238. Epub 2019 Mar 12. PubMed DOI |
| 6. | Combined Menin and EGFR Inhibitors Synergize to Suppress Colorectal Cancer via EGFR-Independent and Calcium-Mediated Repression of SKP2 Transcription. Author: Katona BW1,2, Glynn RA2, Paulosky KE2, Feng Z2, Davis CI3, Ma J2, Berry CT4,5, Szigety KM2, Matkar S2, Liu Y2, Wang H2, Wu Y2,6, He X2, Freedman BD4, Brady DC2, Hua X7. Journal: Cancer Res. 2019 May 1;79(9):2195-2207. doi: 10.1158/0008-5472.CAN-18-2133. Epub 2019 Mar 15. PubMed DOI |
| 7. | Regulation of miRNA Biogenesis and Histone Modification by K63-Polyubiquitinated DDX17 Controls Cancer Stem-like Features. Author: Kao SH1,2, Cheng WC1,2,3, Wang YT4, Wu HT5, Yeh HY1, Chen YJ4, Tsai MH6, Wu KJ7,2,3,8,9,10,11. Journal: Cancer Res. 2019 May 15;79(10):2549-2563. doi: 10.1158/0008-5472.CAN-18-2376. Epub 2019 Mar 15. PubMed DOI |
| 8. | CD317 Activates EGFR by Regulating Its Association with Lipid Rafts. Author: Zhang G1, Li X1, Chen Q1, Li J1, Ruan Q1, Chen YH2, Yang X3, Wan X4. Journal: Cancer Res. 2019 May 1;79(9):2220-2231. doi: 10.1158/0008-5472.CAN-18-2603. Epub 2019 Mar 19. PubMed DOI |
| 9. | Inhibition of miR-328-3p Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian Cancer. Author: Srivastava AK#1, Banerjee A#1,2, Cui T#1, Han C1, Cai S1, Liu L1,3, Wu D1, Cui R4, Li Z5, Zhang X6, Xie G1, Selvendiran K7, Patnaik S2, Karpf AR8, Liu J9, Cohn DE7, Wang QE10,11. Journal: Cancer Res. 2019 May 1;79(9):2314-2326. doi: 10.1158/0008-5472.CAN-18-3668. Epub 2019 Mar 20. PubMed DOI |
| 10. | 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer. Author: Wang Z1,2, Feng X1, Molinolo AA1, Martin D3, Vitale-Cross L3, Nohata N1, Ando M1, Wahba A4, Amornphimoltham P1,5, Wu X1, Gilardi M1, Allevato M1,6, Wu V1,6, Steffen DJ1,6, Tofilon P4, Sonenberg N7, Califano J1, Chen Q8, Lippman SM9, Gutkind JS9,6. Journal: Cancer Res. 2019 Apr 1;79(7):1438-1450. doi: 10.1158/0008-5472.CAN-18-1220. Epub 2019 Mar 20. PubMed DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共11条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
